Celcuity Inc. is under investigation by Pomerantz LLP for possible securities fraud following a delayed commercial launch announcement of its breast cancer drug Revtorpyk. The FDA approved the drug, but the launch was pushed to late Q3 2026, later than analysts expected, causing the stock to fall 17.6% on July 15, 2026. This delay and the subsequent stock drop have raised concerns about the company's disclosures and business practices. Investors are advised to contact Pomerantz LLP if they believe they were affected.
IREN Limited is set to report earnings showing a significant revenue drop from $187.3 million to around $132-142 million year-over-year, with an expected loss per share of approximately -$0.55 compared to last year's profit. The company faces challen...
Real REMAX Group finalized its acquisition of RE/MAX Holdings on August 24, 2026, forming a combined company with over 180,000 agents worldwide. The new entity trades on Nasdaq under the ticker REAX and blends Real's technology platform with RE/MAX's...
Build-A-Bear Workshop reported Q2 earnings per share of $0.70, beating analyst estimates despite a decline from $0.94 last year. However, revenue fell 7.2% year-over-year to $115.29 million, missing expectations and leading to a lowered annual sales ...
Affirm Holdings, a leader in buy now, pay later services, is set to report strong Q2 earnings with an expected EPS of $0.35 and revenue of $1.11 billion, up 26.2% year-over-year. Growth is driven by a 29.3% increase in Gross Merchandise Volume and a ...
Amphenol Corporation plans a 2-for-1 stock split on September 3, 2026, doubling shares while keeping investment value steady. The company shows strong growth, especially in its Communications Solutions segment, driven by AI-related IT demand and acqu...
